尼妥珠单克隆抗体注射液治疗口腔颌面-头颈部鳞癌专家共识

2021-07-30 中国肿瘤科相关专家小组(统称) 实用口腔医学杂志. 2021,37(04)

口腔颌面-头颈部恶性肿瘤发病率位居人类恶性肿瘤的第6位,大部分患者就诊时已到局部晚期阶段,经过手术、放化疗后仍有很高比例的患者会发生局部复发和/或远处转移。针对复发和/或转移性口腔颌面-头颈部鳞癌患者

中文标题:

尼妥珠单克隆抗体注射液治疗口腔颌面-头颈部鳞癌专家共识

发布日期:

2021-07-30

简要介绍:

口腔颌面-头颈部恶性肿瘤发病率位居人类恶性肿瘤的第6位,大部分患者就诊时已到局部晚期阶段,经过手术、放化疗后仍有很高比例的患者会发生局部复发和/或远处转移。针对复发和/或转移性口腔颌面-头颈部鳞癌患者,以EGFR靶向治疗药物为基础的靶向化疗是目前一线治疗常规应用方案。国际上已批准的治疗头颈部肿瘤的靶向药物有尼妥珠单克隆抗体(单克隆抗体,以下简称单抗)和西妥昔单抗,目前西妥昔单抗的指南很多,而尼妥珠单抗在口腔颌面-头颈部恶性肿瘤的应用尚无明确规范。本文结合文献及相关专家的经验,制定专家共识,对尼妥珠单抗的抗肿瘤机制以及目前临床应用情况进行阐述,制定了尼妥珠单抗治疗口腔颌面-头颈部鳞癌的建议方案,供临床医师参考。 

相关资料下载:
[AttachmentFileName(sort=1, fileName=尼妥珠单克隆抗体注射液治疗口腔颌面_头颈部鳞癌专家共识_郭伟.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ba8ff1c002151aad, title= 尼妥珠单克隆抗体注射液治疗口腔颌面-头颈部鳞癌专家共识, enTitle=, guiderFrom=实用口腔医学杂志. 2021,37(04), authorId=0, author=, summary=口腔颌面-头颈部恶性肿瘤发病率位居人类恶性肿瘤的第6位,大部分患者就诊时已到局部晚期阶段,经过手术、放化疗后仍有很高比例的患者会发生局部复发和/或远处转移。针对复发和/或转移性口腔颌面-头颈部鳞癌患者, cover=https://img.medsci.cn/202189/1628442905744_2020535.jpg, journalId=0, articlesId=null, associationId=747, associationName=中国肿瘤科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Fri Jul 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">口腔颌面-头颈部恶性肿瘤发病率位居人类恶性肿瘤的第6位,大部分患者就诊时已到局部晚期阶段,经过手术、放化疗后仍有很高比例的患者会发生局部复发和/或远处转移。针对复发和/或转移性口腔颌面-头颈部鳞癌患者,以EGFR靶向治疗药物为基础的靶向化疗是目前一线治疗常规应用方案。国际上已批准的治疗头颈部肿瘤的靶向药物有尼妥珠单克隆抗体(单克隆抗体,以下简称单抗)和西妥昔单抗,目前西妥昔单抗的指南很多,而尼妥珠单抗在口腔颌面-头颈部恶性肿瘤的应用尚无明确规范。本文结合文献及相关专家的经验,制定专家共识,对尼妥珠单抗的抗肿瘤机制以及目前临床应用情况进行阐述,制定了尼妥珠单抗治疗口腔颌面-头颈部鳞癌的建议方案,供临床医师参考。&nbsp;</span></p>, tagList=[TagDto(tagId=24083, tagName=头颈部鳞癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=30, categoryName=耳鼻咽喉科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=24083, guiderKeyword=头颈部鳞癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9288, appHits=97, showAppHits=0, pcHits=958, showPcHits=8802, likes=2, shares=10, comments=7, approvalStatus=1, publishedTime=Wed Aug 11 13:54:45 CST 2021, publishedTimeString=2021-07-30, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Mon Aug 09 01:15:15 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 14:30:42 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=尼妥珠单克隆抗体注射液治疗口腔颌面_头颈部鳞癌专家共识_郭伟.pdf)])
尼妥珠单克隆抗体注射液治疗口腔颌面_头颈部鳞癌专家共识_郭伟.pdf
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1084601, encodeId=53f61084601d1, content=搬走学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de521584663, createdName=369826579, createdTime=Mon Dec 27 09:51:07 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007453, encodeId=972b100e453bc, content=好的,下载学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2755571938, createdName=sherlock, createdTime=Thu Aug 12 22:57:50 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007126, encodeId=045c100e1260b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210811/f57c872099474e4296cf2003dc83f244/2c7b6201c126492e826e645953c5f35d.jpg, createdBy=a84f5207031, createdName=1475010fm89暂无昵称, createdTime=Wed Aug 11 23:14:28 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006243, encodeId=48321006243a8, content=学习了学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Mon Aug 09 09:30:20 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006203, encodeId=845910062038c, content=会耐药吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Mon Aug 09 06:13:21 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-12-27 369826579

    搬走学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1084601, encodeId=53f61084601d1, content=搬走学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de521584663, createdName=369826579, createdTime=Mon Dec 27 09:51:07 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007453, encodeId=972b100e453bc, content=好的,下载学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2755571938, createdName=sherlock, createdTime=Thu Aug 12 22:57:50 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007126, encodeId=045c100e1260b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210811/f57c872099474e4296cf2003dc83f244/2c7b6201c126492e826e645953c5f35d.jpg, createdBy=a84f5207031, createdName=1475010fm89暂无昵称, createdTime=Wed Aug 11 23:14:28 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006243, encodeId=48321006243a8, content=学习了学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Mon Aug 09 09:30:20 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006203, encodeId=845910062038c, content=会耐药吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Mon Aug 09 06:13:21 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-12 sherlock

    好的,下载学习下

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1084601, encodeId=53f61084601d1, content=搬走学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de521584663, createdName=369826579, createdTime=Mon Dec 27 09:51:07 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007453, encodeId=972b100e453bc, content=好的,下载学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2755571938, createdName=sherlock, createdTime=Thu Aug 12 22:57:50 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007126, encodeId=045c100e1260b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210811/f57c872099474e4296cf2003dc83f244/2c7b6201c126492e826e645953c5f35d.jpg, createdBy=a84f5207031, createdName=1475010fm89暂无昵称, createdTime=Wed Aug 11 23:14:28 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006243, encodeId=48321006243a8, content=学习了学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Mon Aug 09 09:30:20 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006203, encodeId=845910062038c, content=会耐药吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Mon Aug 09 06:13:21 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-11 1475010fm89暂无昵称

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1084601, encodeId=53f61084601d1, content=搬走学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de521584663, createdName=369826579, createdTime=Mon Dec 27 09:51:07 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007453, encodeId=972b100e453bc, content=好的,下载学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2755571938, createdName=sherlock, createdTime=Thu Aug 12 22:57:50 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007126, encodeId=045c100e1260b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210811/f57c872099474e4296cf2003dc83f244/2c7b6201c126492e826e645953c5f35d.jpg, createdBy=a84f5207031, createdName=1475010fm89暂无昵称, createdTime=Wed Aug 11 23:14:28 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006243, encodeId=48321006243a8, content=学习了学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Mon Aug 09 09:30:20 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006203, encodeId=845910062038c, content=会耐药吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Mon Aug 09 06:13:21 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-09 智慧药

    学习了学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1084601, encodeId=53f61084601d1, content=搬走学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de521584663, createdName=369826579, createdTime=Mon Dec 27 09:51:07 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007453, encodeId=972b100e453bc, content=好的,下载学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2755571938, createdName=sherlock, createdTime=Thu Aug 12 22:57:50 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007126, encodeId=045c100e1260b, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210811/f57c872099474e4296cf2003dc83f244/2c7b6201c126492e826e645953c5f35d.jpg, createdBy=a84f5207031, createdName=1475010fm89暂无昵称, createdTime=Wed Aug 11 23:14:28 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006243, encodeId=48321006243a8, content=学习了学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Mon Aug 09 09:30:20 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006203, encodeId=845910062038c, content=会耐药吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Mon Aug 09 06:13:21 CST 2021, time=2021-08-09, status=1, ipAttribution=)]
    2021-08-09 与狼共舞

    会耐药吗

    0

拓展阅读

口腔颌面头颈部鳞癌超声热化疗中国专家共识

中国肿瘤科相关专家小组(统称) · 2020-05-30

尼妥珠单克隆抗体注射液治疗口腔颌面—头颈部鳞癌专家共识

中国肿瘤科相关专家小组(统称) · 2021-08-01

头颈部鳞癌免疫检查点抑制剂治疗专家共识

四川大学华西医院头颈肿瘤科 · 2022-11-30